Safety of Intravenous Lidocaine Infusions
Completed
- Conditions
- Neuropathic Pain
- Registration Number
- NCT01091935
- Lead Sponsor
- Lawson Health Research Institute
- Brief Summary
The purpose of this study is to prospectively determine the side effects profile in adults with neuropathic pain receiving intravenous infusions of lidocaine 5 mg per kg of lean body weight, infused over 45 minutes.
- Detailed Description
Eligibility Criteria:
Adults \> 18 yrs with chronic central or peripheral neuropathic pain at the St Joseph's Health Care Pain Clinic between June and December 2009.
Outcome measures: All side effects spontaneously reported. Sedation, nausea, dizziness by Visual Analog Score Q 15 minutes; hemodynamic data q 5 minutes during and after infusion for 30 minutes.
Daily diary of side effects and Visual Analogue score of Pain for 7 days post-infusion.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
- Adult outpatients > 18 years < 80 years diagnosed with chronic neuropathic pain
Exclusion Criteria
- Unable to provide informed consent
- Unable to speak and understand English
- Liver, kidney, or cardiac failure
- Allergy to Lidocaine
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
St Joseph's Health Care
🇨🇦London, Ontario, Canada